Ptc Therapeutics (PTCT) Capital Leases (2020 - 2025)
Historic Capital Leases for Ptc Therapeutics (PTCT) over the last 6 years, with Q3 2025 value amounting to $13.8 million.
- Ptc Therapeutics' Capital Leases fell 1117.89% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year decrease of 1117.89%. This contributed to the annual value of $15.6 million for FY2024, which is 936.92% down from last year.
- Per Ptc Therapeutics' latest filing, its Capital Leases stood at $13.8 million for Q3 2025, which was down 1117.89% from $13.8 million recorded in Q2 2025.
- Ptc Therapeutics' 5-year Capital Leases high stood at $20.1 million for Q3 2021, and its period low was $13.8 million during Q1 2025.
- Its 5-year average for Capital Leases is $17.2 million, with a median of $17.2 million in 2023.
- As far as peak fluctuations go, Ptc Therapeutics' Capital Leases tumbled by 1298.7% in 2021, and later tumbled by 674.71% in 2022.
- Ptc Therapeutics' Capital Leases (Quarter) stood at $20.1 million in 2021, then decreased by 7.09% to $18.7 million in 2022, then decreased by 7.98% to $17.2 million in 2023, then decreased by 9.37% to $15.6 million in 2024, then decreased by 11.18% to $13.8 million in 2025.
- Its Capital Leases stands at $13.8 million for Q3 2025, versus $13.8 million for Q2 2025 and $13.8 million for Q1 2025.